Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|August 2, 2004
- Pharmaceutical Technology-08-02-2004
- Volume 28
- Issue 8
Photosensitivity of Internal Standard Valerophenone Used in USP Ibuprofen Bulk Drug and Tablet Assay and Its Effect on the Quantitation of Ibuprofen and Its Impurities
Author(s)Ranga Velagaleti, PhD
The results of forced degradation studies indicate the need for alternatives to valerophenone as an internal standard calibration for quantifying ibuprofen in bulk drug and tablet assay samples.
Advertisement
Articles in this issue
about 22 years ago
Stable Isotopic Characterization of Analgesic Drugsabout 22 years ago
August 2004about 22 years ago
Increased Outsourcing Driving Investments in CRO Industryabout 22 years ago
E-Health Information Campaign Shapes Pharmaceutical Regulationabout 22 years ago
In the Spotlight-August 2004about 22 years ago
Interphex Delivers Packaging Solutionsabout 22 years ago
Vapor-Phase Hydrogen Peroxide Resistance of Environmental Isolatesabout 22 years ago
Decoding the US PharmacopeiaAdvertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Advertisement
Advertisement